8.37 (0.60%)
As of Mar 03, 2023
Source:
Concert Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company that is developing CTP-543, a Janus Kinase 1 and Janus Kinase 2 (JAK 1/2) inhibitor that we discovered through the application of our DCE Platform
| Country | United States |
| Headquarters | lexington, massachusetts |
| Phone Number | 781-860-0045 |
| Industry | manufacturing |
| CEO | Roger D. Tung |
| Website | concertpharma.com |